Merck & Co. Amortization decreased by 4.3% to $931.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 55.9%, from $597.00M to $931.00M. Over 4 years (FY 2021 to FY 2025), Amortization shows an upward trend with a 14.3% CAGR.
Higher amortization often signals significant past M&A activity or heavy investment in intellectual property, whereas lower levels suggest fewer intangible assets being written off.
This represents the non-cash charge associated with the write-down of intangible assets, such as patents, software, or a...
Standard for technology companies with significant intellectual property portfolios; peers often report this separately from tangible depreciation.
operating_adjustment_for_amortization| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $357.00M | $360.00M | $405.00M | $699.00M | $464.00M | $460.00M | $462.00M | $543.00M | $477.00M | $562.00M | $462.00M | $473.00M | $614.00M | $633.00M | $675.00M | $597.00M | $601.00M | $622.00M | $973.00M | $931.00M |
| QoQ Change | — | +0.8% | +12.5% | +72.6% | -33.6% | -0.9% | +0.4% | +17.5% | -12.2% | +17.8% | -17.8% | +2.4% | +29.8% | +3.1% | +6.6% | -11.6% | +0.7% | +3.5% | +56.4% | -4.3% |
| YoY Change | — | — | — | — | +30.0% | +27.8% | +14.1% | -22.3% | +2.8% | +22.2% | +0.0% | -12.9% | +28.7% | +12.6% | +46.1% | +26.2% | -2.1% | -1.7% | +44.1% | +55.9% |
| Segment | Q1 '23 | Q3 '23 |
|---|---|---|
| Alliance revenue - Lenvima | $72.00M | $81.00M |
| Total | $543.00M | $562.00M |
Alliance revenue - Lenvima was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.